Bukwang Pharmaceutical Co., Ltd. announced attendance of the 68th Spring Symposium of Korean Dermatological Association 2016, held at Ramada Hotel in Cheong-ju.
The RD (Respiratory and Dermatology) department of Bukwang participated in the event and actively promoted their key products Nadixa cream (nadifloxacin) for acne and Dermofix cream (Sertaconazole nitrate) for athlete’s foot. Bukwang is currently operating its sales force in divisions focused on each product in order to maximize the sales teams’ potential.
Both Nadixa cream and Dermofix cream are branded dermatological products developed by Ferrer in Spain. Nadixa cream is very effective against acne due to its excellent antibacterial activity. Also, Nadixa does not easily induce antibacterial resistance and boasts superior safety profile. Dermofix cream has a dual mechanism of fungicidal and fungistatic activity, thereby producing rapid and strong efficacy against dermatophytosis, candidiasis and leukoderma.
Although the event was held outside Seoul, more than 40 pharmaceutical companies and 700 dermatologists participated in the symposium this year and made the event a great success.